This educational program is intended for medical oncologists, nurses, pharmacists, and other healthcare professionals who treat patients with CLL/SLL.
Upon completion of this activity, participants should be able to:
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Farrukh Awan, MD, MS
Associate Professor of Internal Medicine
Division of Hematology
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Farrukh T. Awan, MD, MS: consultant/advisor: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, Bristol-Myers Squibb, Cardinal Health, Caribou Biosciences, Celgene, Dava Oncology, Epizyme, Genentech, Gilead Sciences, Incyte, Janssen, Johnson & Johnson, Karyopharm, Kite Pharma, MEI Pharma, Merck, Pharmacyclics, Verastem.
Nicole Lamanna, MD
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York
Nicole Lamanna, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Genentech, Janssen, Pharmacyclics.
Jerfiz Constanzo, PhD, MBA
Jerfiz D. Constanzo, PhD, MBA, has no relevant financial relationships to disclose.
Clinical Care Options, LLC
Gordon Kelley has no relevant financial relationships to disclose.
Associate Managing Editor
Krista Marcello has no relevant financial relationships to disclose.
Product Director, Hematology/Oncology
Clinical Care Options, LLC
Jim Mortimer has no relevant financial relationships to disclose.
Kevin Obholz, PhD
Editorial Director, Hematology/Oncology
Kevin Obholz, PhD, has no relevant financial relationships to disclose.
Timothy A. Quill, PhD
Senior Managing Editor
Timothy A. Quill, PhD, has no relevant financial relationships to disclose.
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and Clinical Care Options, LLC (CCO). Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 1.0 contact hour(s) in the area of pharmacology.
Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-115-H01-P
Type of Activity: Knowledge
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Learner information will be shared through the ACCME's Program and Activity Reporting System (PARS).
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 28, 2022, through October 27, 2023:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
This program has been made available online.
The goal of this activity is to improve the knowledge, competence, and confidence of learners to apply practice-changing clinical data and expert recommendations to optimize the use of current and emerging therapeutic strategies with BTKi in the care of their patients with CLL/SLL.